Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Odinwell AB is a prominent player in the healthcare and biotechnology sector. The company's primary focus is on developing innovative medical technology solutions aimed at improving patient care and outcomes. Odinwell AB specializes in advanced wound care products, leveraging cutting-edge research and technology to address critical needs in wound management. Their offerings are designed to enhance healing processes, reduce patient recovery times, and improve overall health metrics. Operating in a dynamic industry, Odinwell AB contributes significantly to the healthcare market by providing solutions that help healthcare professionals deliver more effective care. The company is strategically positioned to influence the biotechnology landscape with its dedication to scientific advancements and technology-driven approaches.
kr 0.02
kr 0.00 (-7.53%)
Live · 11:06 PM · Twelve Data
Negative free cash flow of -kr 9M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 106K
Net Income (TTM)
-kr 5M
▼ -11.8% YoY
Op. Margin
-5265.24%
ROIC
-13.96%
Cash Flow & Balance Sheet
FCF (TTM)
-kr 8M
▲ +12.0% YoY
Op. Cash Flow (TTM)
-kr 5M
▼ -19.5% YoY
Net Debt
-kr 5M
Net Cash Position
Cash & Equiv.
kr 5M
Continue Research
Odinwell AB (ODIN.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Odinwell AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Odinwell AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -5,265.2% operating margin and a -14.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ODIN.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.